Research Article

Human Papillomavirus Positivity in the Anal Canal in HIV-Infected and HIV-Uninfected Men Who Have Anal Sex with Men in Guangzhou, China: Implication for Anal Exams and Early Vaccination

Xuqi Ren,1 Wujian Ke,1 Heping Zheng,1 Ligang Yang,1 Shujie Huang,1 Xiaolin Qin,1 Bin Yang,1 and Huachun Zou2,3

1Guangdong Provincial Center for Skin Disease & STI Control, Guangzhou, Guangdong 510091, China
2School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong 510085, China
3Kirby Institute, The University of New South Wales, Sydney, NSW 2052, Australia

Correspondence should be addressed to Bin Yang; yangbin101@hotmail.com and Huachun Zou; zouhuachun@mail.sysu.edu.cn

Received 2 August 2016; Accepted 29 November 2016; Published 4 January 2017

Academic Editor: Llibre Josep-Maria

Copyright © 2017 Xuqi Ren et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. The epidemiology of HPV in men who have sex with men (MSM) in Guangzhou, China, had not been reported previously. Methods. HIV-infected and HIV-uninfected MSM were recruited from a Guangzhou-based MSM clinic in 2013. Sociodemographic characteristics and sexual behaviors were collected. An anal cytological sample was taken for HPV testing. Results. We recruited 79 HIV-infected and 85 HIV-uninfected MSM. The median age was 26 years in both groups. The positivities of anal HPV of any type (81.0% versus 48.2%), any high risk type (50.6% versus 27.1%), any low risk type (55.7% versus 31.8%), and any 9-valent vaccine type (74.7% versus 36.5%) were all significantly higher among HIV-infected compared to that among HIV-negative MSM (p < 0.05). The great majority of HPV-infected MSM were infected with 9-valent vaccine types (59 out of 64 HIV-infected and 31 out of 41 HIV-uninfected). Anal bacterial infections were associated with higher anal HPV positivity and greater number of anal HPV types. Conclusion. Sexually active MSM in Guangzhou, especially those infected with HIV, had high and multiple HPV detections. The majority of these cases were potentially preventable by HPV vaccine. Regular anal exams and early HPV vaccination are warranted in this population.

1. Introduction

Human papillomavirus (HPV) is one of the most common sexually transmitted infections (STIs) seen in the anogenital area, with high prevalence and incidence among men who have sex with men (MSM) [1–3]. A meta-analysis of global data on HPV in MSM found prevalence of anal HPV to be 93% in HIV-positive MSM and 64% in HIV-negative MSM and these rates did not decrease with increasing age [4]. HPV can cause symptoms such as anogenital warts and intraepithelial neoplasia and squamous-cell carcinoma in the anal canal [5]. These symptoms cause high psychological and financial burdens in the MSM population. Risk factors, including unprotected anal intercourse (UAI) and multiple sex partners, render MSM vulnerable to anal HPV infection, especially among those who are infected with HIV [6, 7]. A meta-analysis found significant difference in the incidence of anal cancer between HIV-infected and HIV-uninfected MSM: 46 versus 5 per 100,000 person-years [4].

Studies in China reported high prevalence of anal HPV among MSM irrespective of HIV status: 65.3–71.4% in Beijing [8–10], 73.0% in Taiyuan [11], 52.7% in Xi’an [12], 68.7% in Chengdu [11], and 36.4% in Shenzhen [13]. Among HIV-infected MSM the HPV prevalence was even higher, ranging from 71.4% in Shenzhen [13] to 99.0% in Xi’an [12]. Guangzhou is the largest city in southern China with a population of over 13 million in 2014 [14]. It was estimated that there were around 25,000 MSM living in Guangzhou [15].
However until now there had been no study that reported on HPV infection among MSM in this city. Our study aimed to clarify the severity of and factors associated with HPV infection among MSM in Guangzhou, comparing HIV-infected to HIV-uninfected ones.

2. Methods

2.1. Study Population. This study was conducted between January and October 2013 at the STD Clinic of the Lingnan Fellows Health Support Center, the largest MSM health support NGO group in Guangzhou. We recruited HIV-infected MSM from those who attended the clinic for periodical CD4+ T cell count test and HIV-uninfected MSM from those who attended the clinic for HIV testing and who tested negative. Eligible participants were males aged 18 years or older who had had receptive anal sex with another man in the past 12 months. The study was reviewed and monitored by the Ethics Committees of Guangdong Provincial Dermatology Hospital, Guangzhou, China. Written informed consent was obtained from all participants before data and sample collection.

2.2. Data Collection. A self-administered questionnaire was collected. The questionnaire included information on socio-demographic characteristics (e.g., age, ethnicity, education, marital status, and career), sexual behaviors (e.g., gender of first sex partner, heterosexual and homosexual behaviors, and condom use in the past three months), knowledge about sexual partner's STD status, experience of commercial sex, marital status, and career), sexual behaviors (e.g., gender of first sex partner, heterosexual and homosexual behaviors, and condom use in the past three months), frequency of frequency of male sex partners in the past 3 months, and frequency of alcohol use. A unique code was used to link questionnaire to specimens of a participant. Personal contact information, which was blinded to researchers, was kept by the STD Clinic of Lingnan Fellows Health Support Center for test results feedback and data validation.

2.3. Sample Processing. A blood sample was collected from HIV-negative/unknown subjects for HIV serological assessment. The HIV serologic status was determined by enzyme-linked immunoassay (ELISA, Wantai Biological Medicine Company, Beijing, China). Positive samples by ELISA were further confirmed by using the HIV-1/2 Western blot assay (HIV Blot 2.2 WB; Genelabs Diagnostics, Singapore). HIV serology was performed at the Guangzhou Center for Disease Control. An anal swab sample was taken to test for chlamydia, gonorrhea, and Mycoplasma genitalium using nucleic acid amplification test (DaAn Gene Co., Guangzhou, China) as previously described [16].

A clinician checked warts in the anal canal with the help of an anal speculum, after the collection of a cytological sample. A cytological sample was obtained around the dentate line in the anal canal using a small soft cytology brush (HybriBio, Chaozhou, China). The swab sample was coded and stored at −70°C before further processing. HPV DNA was extracted at Cell Lysate Kit (HybriBio, Chaozhou, China) according to the manufacturer’s instructions. HPV DNA was amplified by using MY09/11 primers [17] and the amplified fragment was about 450 bp. The DNA sequences within the L1 region of HPV were used to detect generic HPV DNA. Amplification was carried out in 50 µL of reaction mixture (1x GoTaq PCR buffer (Promega, USA), 0.2 mM deoxynucleotide triphosphates (dNTPs, Thermo, USA), 1.5 mM MgCl2 (Sigma-Aldrich, USA), 1 µmole of each primer, 1.25 units (U) of GoTaq DNA Polymerase (Promega, USA) and 2 µL of DNA sample). The amplified condition was 95°C for 2 min of denaturation and then 40 cycles of amplification: 95°C for 1 min of denaturation, 55°C for 1 min of annealing, 72°C for 1 min of extension, and final extension at 72°C for 10 min by using the GeneAmp RCR System 9600 (Perkin Elmer, United States). PCR products were analyzed on 2.0% agarose gel with GeneGreen Nucleic Acid Dye (TianGen, China), visualized by the Tanon 5299 Multi (Ewell, China), and their molecular weights were determined by comparison with a DL 1000-bp DNA ladder (TaKaRa, Japan).

All samples were tested by PCR methods three single times and confirmed by Sangon Biotech, China.

HPV genotype screening was conducted using (1) sequencing tests: HPV positive PCR products were purified by PureLink Quick Gel Extraction Kit (Invitrogen, USA) and the sequencing services were purchased from Sangon Biotech, China. The assembled sequences were submitted to BLAST alignment (https://www.ncbi.nlm.nih.gov/blast), against sequences available in GenBank; (2) HPV reverse dot blot genotyping: HPV genotyping was detected according to the manufacturer’s instructions by using the HPV reverse dot blot genotyping kit and the automatic nucleic acid hybridization device (Guangzhou LBP Medical Technology Co., Ltd., Guangzhou, China), which can detect 28 HPV subtypes (6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 66, 67, 71, 81, 82, and 84). We classified HPV types into high risk (HR) types (16, 18, 26, 31, 33, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 56, 58, 59, 66, 68, 71, 82) and low risk (LR) types (6, 11, 14, 40, 42, 43, 44, 54, 61, 81, 84), based on their association with cervical cancer [18].

2.4. Statistical Analysis. A sample size of 79 HIV-infected and 86 HIV-uninfected MSM was required to provide acceptable 95% confidence intervals (CIs) around the expected proportion of men with anal HPV. Median and interquartile range (IQR) were used for continuous variables. Proportions were used for categorical variables. The chi-squared test was used to compare proportions between groups. Rank sum test was used to compare median of anal HPV type detected 2.4. Statistical Analysis. A sample size of 79 HIV-infected and 86 HIV-uninfected MSM was required to provide acceptable 95% confidence intervals (CIs) around the expected proportion of men with anal HPV. Median and interquartile range (IQR) were used for continuous variables. Proportions were used for categorical variables. The chi-squared test was used to compare proportions between groups. Rank sum test was used to compare median of anal HPV type detected between groups. Univariate and multivariate logistic regression models were used to calculate odds ratios to estimate the association between potential risk factors and HPV infection. Variables with a \( p < 0.1 \) using univariate models were entered into the multivariate regression model. Variables with a \( p > 0.1 \) using univariate models yet deemed as potential confounders were also entered into the multivariate regression model, including age at enrollment, number of male sex partners in the past 3 months, and frequency of condom use in anal sex in the past 3 months. Data were entered using EpiData version 3.0 (The EpiData Association Odense, Denmark) and statistical analyses conducted using STATA version 13.0 (StataCorp, Texas).
Table 1: Demographic characteristics among HIV-infected and HIV-uninfected men who have sex with men in Guangzhou.

| Demographic characteristic      | HIV-infected Number/median | IQR/% | HIV-uninfected Number/median | IQR/% | All Number/median | IQR/% |
|---------------------------------|----------------------------|-------|------------------------------|-------|------------------|-------|
| Age at recruitment (year)       | 26.0 20–38                 |       | 26.0 20–39                   |       | 26.0 19–40       |       |
| 18–24                           | 29 36.7                    |       | 35 41.2                      |       | 64 39.0          |       |
| 25–34                           | 42 53.2                    |       | 44 51.8                      |       | 86 52.4          |       |
| ≥35                             | 8 10.1                     |       | 6 7.1                        |       | 14 8.5           |       |
| Education level*                |                            |       |                              |       |                  |       |
| Middle school or less           | 19 24.1                    |       | 13 15.3                      |       | 32 19.5          |       |
| Technical diploma               | 26 32.9                    |       | 21 24.7                      |       | 47 28.7          |       |
| University or above             | 34 43.0                    |       | 51 60.0                      |       | 85 51.8          |       |
| Ethnicity                       |                            |       |                              |       |                  |       |
| Han                             | 76 96.2                    |       | 79 92.9                      |       | 155 94.5         |       |
| Other                           | 3 3.8                      |       | 6 7.1                        |       | 9 5.5            |       |
| Profession                      |                            |       |                              |       |                  |       |
| Student                         | 12 15.2                    |       | 18 21.2                      |       | 30 18.3          |       |
| Service industry                | 16 20.3                    |       | 21 24.7                      |       | 37 22.6          |       |
| Private company                 | 15 19.0                    |       | 10 11.8                      |       | 25 15.2          |       |
| Other                           | 36 45.6                    |       | 36 42.4                      |       | 72 43.9          |       |
| Marital status                  |                            |       |                              |       |                  |       |
| Unmarried/divorced              | 71 89.9                    |       | 79 92.9                      |       | 14 8.5           |       |
| Married                         | 8 10.1                     |       | 6 7.1                        |       | 150 91.5         |       |
| Frequency of drinking           |                            |       |                              |       |                  |       |
| Every day or often              | 5 6.3                      |       | 6 7.1                        |       | 11 6.7           |       |
| Sometimes                       | 25 31.7                    |       | 30 35.3                      |       | 55 33.5          |       |
| Seldom or never                 | 49 62.0                    |       | 49 57.7                      |       | 98 59.8          |       |

Notes. *0.05 < p < 0.10.

3. Results

3.1. Participant Characteristics. We recruited 79 HIV-infected and 85 HIV-uninfected MSM. As shown in Table 1, HIV-infected MSM and HIV-uninfected MSM were comparable in age (median 26 years for both), ethnicity (96.2% versus 92.9% were Han ethnic), profession (15.2% versus 21.2% were students), marital status (89.9% versus 92.9% were unmarried), and frequency of drinking (p for all > 0.1). HIV-infected MSM had slightly less education compared to HIV-uninfected MSM (43.0% versus 60.0% had university education or above, p < 0.1). Anal warts were detected in 10.6% of HIV-infected MSM and 3.8% of HIV-uninfected MSM (p = 0.095). Sixty-three point three percent of HIV-infected MSM and 30.6% of HIV-uninfected MSM were detected with either anal chlamydia, gonorrhea, or mycoplasma (p < 0.001).

3.2. Sexual Behaviors. As shown in Table 2, the majority of both HIV-infected (81.0%) and HIV-uninfected MSM (83.5%) had sex with men only. Median age at first anal intercourse (AFAI) with a man (23.7% versus 21.7% with AFAI at 18 years or younger), frequency of condom use in anal sex in the past 3 months (46.8% versus 57.7% always used a condom), sexual experience with a woman in the past 3 months (6.3% versus 8.2%), and commercial sex experience (8.9% versus 4.7%) were similar in both groups of men (p for all > 0.1). HIV-infected MSM had slightly less male sex partners in the past 3 months compared to HIV-uninfected MSM, even though the difference was not statistically significant (p < 0.1).

3.3. Positivity of HPV DNA. All samples were beta-globin positive. The proportion of men with each of the 28 HPV types detected by PCR is shown in Table 3. The positivities of anal HPV of any type (81.0% versus 48.2%, p < 0.001), any high risk type (50.6% versus 27.1%, p = 0.002), any low risk type (55.7% versus 31.8%, p = 0.002), any 4-valent vaccine type (64.6% versus 32.9%, p < 0.001), and any 9-valent vaccine type (74.7% versus 36.5%, p < 0.001) were all significantly higher among HIV-infected MSM compared to those among HIV-negative MSM. This tendency also applied to HPV 18, HPV 6/11, and HPV 16/18 (p for all < 0.05). Other individual HPV types including HPV 6, 33, 39, 52, and 84 were slightly higher among HIV-infected MSM compared to those among HIV-negative MSM, even though the difference was not statistically significant (p < 0.1). In the meantime, multiple HPV infection was seen in 30.4% of HIV-infected MSM and 16.4% of HIV-uninfected MSM (p =
Table 2: Sexual behaviors among HIV-infected and HIV-uninfected men who have sex with men in Guangzhou.

| Sexual behaviors                      | HIV-infected | HIV-uninfected | All | n | %  | n | %  | N | %  |
|---------------------------------------|--------------|----------------|-----|---|----|---|----|---|----|
| Gender of sex partner                 |              |                |     |   |     |   |     |   |    |
| Mostly with women and sometimes with men | 4 | 5.1 | 6 | 7.1 | 10 | 6.1 |
| Mostly with men and sometimes with women | 11 | 13.9 | 8 | 9.4 | 19 | 11.6 |
| With men only                         | 64 | 81.0 | 71 | 83.5 | 135 | 82.3 |
| AFAI (year)                           | Median = 19 | Median = 19 | Median = 19 |
| ≤18                                   | 18 | 23.7 | 18 | 21.7 | 36 | 22.6 |
| >18                                   | 58 | 76.3 | 65 | 78.3 | 123 | 77.4 |
| Type of first sex                     |              |                |     |   |     |   |     |   |    |
| Mutual masturbation                  | 33 | 41.8 | 41 | 48.2 | 74 | 45.1 |
| Oral sex                              | 15 | 19.0 | 16 | 18.8 | 31 | 18.9 |
| Anal sex                              | 28 | 35.4 | 25 | 29.4 | 53 | 32.3 |
| Cervical sex                          | 3 | 3.8 | 3 | 3.5 | 6 | 3.7 |
| Sex with a man in p3m*                |              |                |     |   |     |   |     |   |    |
| No                                    | 13 | 16.5 | 6 | 7.1 | 145 | 88.4 |
| Yes                                   | 66 | 83.5 | 79 | 92.9 | 19 | 11.6 |
| Number of male sex partners in p3m*   | Median = 2   | Median = 2     | Median = 2 |
| 0                                     | 8 | 11.1 | 3 | 3.7 | 11 | 7.1 |
| 1                                     | 32 | 44.4 | 50 | 61.0 | 82 | 53.3 |
| ≥2                                    | 32 | 44.4 | 29 | 35.4 | 61 | 39.6 |
| Frequency of condom use with men in p3m |          |                |     |   |     |   |     |   |    |
| Always                                | 37 | 46.8 | 49 | 57.7 | 86 | 52.4 |
| Sometimes                             | 33 | 41.8 | 25 | 29.4 | 58 | 35.4 |
| Never                                 | 9 | 11.4 | 11 | 12.9 | 20 | 12.2 |
| Sex with a woman in p3m               |              |                |     |   |     |   |     |   |    |
| Yes                                   | 5 | 6.3 | 7 | 8.2 | 12 | 7.3 |
| No                                    | 74 | 93.7 | 78 | 91.8 | 152 | 92.7 |
| Commercial sex experience             |              |                |     |   |     |   |     |   |    |
| Yes                                   | 7 | 8.9 | 4 | 4.7 | 11 | 6.7 |
| No                                    | 72 | 91.1 | 81 | 95.3 | 153 | 93.3 |

Notes. *0.05 < p < 0.10.

0.035). HIV-infected MSM had significantly more types of any HPV infection, any 4-valent vaccine type HPV infection, and any 9-valent vaccine type HPV infection compared to HIV-uninfected MSM (median 1 versus 0, p for both < 0.05). The great majority of HPV-infected MSM were infected with 9-valent vaccine types (59 out of 64 HIV-infected ones and 31 out of 41 HIV-uninfected ones).

3.4. Factors Associated with Anal HPV Positivity. In the multivariate logistic regression model as shown in Table 4, after accounting for other potential confounders: MSM who had an STI detection (including anal chlamydia, anal gonorrhea, or anal mycoplasma) were 2.5 (95% CI: 1.1–6.0) times more likely to be infected with any anal HPV compared to those who had no STI detection; and MSM who had HIV were 4.1 (95% CI: 1.8–9.3) times more likely to be infected with any anal HPV compared to those HIV-uninfected. Rank sum test showed that MSM infected with anal chlamydia (p = 0.003) and anal gonorrhea (p = 0.058) had greater number of anal HPV types detected.

4. Discussion
This was the first study to report anal HPV positivity among MSM in Guangzhou, China. We found, among these predominantly young and sexually experienced MSM, anal
Table 3: Detection of anal HPV among HIV-infected and HIV-uninfected men who have sex with men in Guangzhou.

(a) DNA positivity

|                      | HIV-infected (N = 79) | HIV-uninfected (N = 85) | All (N = 164) |
|----------------------|-----------------------|-------------------------|---------------|
| Any type tested**    | 64                    | 81.0                    | 105           | 64.0          |
| High risk types      |                       |                         |               |
| Any high risk types**| 40                    | 50.6                    | 63            | 38.4          |
| HPV 16               | 17                    | 21.5                    | 29            | 17.7          |
| HPV 18**             | 8                     | 10.1                    | 10            | 6.1           |
| HPV 26               | 2                     | 2.5                     | 3             | 1.8           |
| HPV 31               | 2                     | 2.5                     | 2             | 1.2           |
| HPV 33*              | 7                     | 8.9                     | 9             | 5.5           |
| HPV 35               | 1                     | 1.3                     | 2             | 1.2           |
| HPV 39*              | 3                     | 3.8                     | 3             | 1.8           |
| HPV 45               | 1                     | 1.3                     | 2             | 1.2           |
| HPV 51               | 2                     | 2.5                     | 4             | 2.4           |
| HPV 52*              | 8                     | 10.1                    | 11            | 6.7           |
| HPV 53               | 2                     | 2.5                     | 5             | 3.1           |
| HPV 56               | 2                     | 2.5                     | 2             | 1.2           |
| HPV 58               | 6                     | 7.6                     | 8             | 4.9           |
| HPV 59               | 5                     | 5.1                     | 6             | 3.7           |
| HPV 66               | 2                     | 2.5                     | 4             | 2.4           |
| HPV 68               | 5                     | 6.3                     | 8             | 4.9           |
| HPV 73               | 0                     | 0                      | 1             | 0.6           |
| HPV 82               | 1                     | 1.3                     | 3             | 1.8           |
| Low risk types       |                       |                         |               |
| Any low risk type**  | 44                    | 55.7                    | 71            | 43.3          |
| HPV 6*               | 23                    | 29.1                    | 34            | 20.7          |
| HPV 11               | 15                    | 19.0                    | 24            | 14.6          |
| HPV 40               | 3                     | 3.8                     | 4             | 2.4           |
| HPV 42               | 4                     | 5.1                     | 5             | 3.1           |
| HPV 43               | 3                     | 3.8                     | 5             | 3.1           |
| HPV 44               | 2                     | 2.5                     | 3             | 1.8           |
| HPV 54               | 2                     | 2.5                     | 3             | 1.8           |
| HPV 61               | 2                     | 2.5                     | 5             | 3.1           |
| HPV 81               | 0                     | 0                      | 2             | 1.2           |
| HPV 84*              | 0                     | 0                      | 3             | 1.8           |
| HPV 6/11**           | 36                    | 45.6                    | 54            | 32.9          |
| HPV 16/18**          | 25                    | 31.7                    | 39            | 23.8          |
| Any 4-valent vaccine type** | 51 | 64.6 | 28 | 32.9 | 79 | 48.2 |
| HPV 16/18/31/33/45/52/58** | 35 | 44.3 | 19 | 22.4 | 54 | 32.9 |
| Any 9-valent vaccine type** | 59 | 74.7 | 31 | 36.5 | 90 | 54.9 |

(b) Detection of multiple HPV types

|                      | HIV-infected (N = 79) | HIV-uninfected (N = 85) | All (N = 164) |
|----------------------|-----------------------|-------------------------|---------------|
| Any type             |                       |                         |               |
| Median, IQR**        | 1, 0–5                | 0, 0–4                  | 1, 0–6        |
HPV positivity in HIV-infected ones was almost twice as high as that in HIV-uninfected ones, and detection of anal chlamydia, gonorrhea, or mycoplasma was associated with both higher anal HPV positivity and greater number of anal HPV types detected.

The rates of anal HPV positivity among both HIV-infected and HIV-uninfected MSM in our study were similar to that reported among MSM in northern and middle China [8–10,12]. However, these rates were higher than that reported among MSM in Shenzhen (71.4% and 33.8%), another large city right next to Guangzhou [13]. The reason might be that men in our study had more sex partners compared to those in the Shenzhen study (median 2 versus 1.5 in the past 3 months). The Shenzhen study did not recruit HIV-infected and HIV-uninfected MSM separately and only recruited 28 HIV-infected MSM. As a result, the point estimate of HPV positivity among HIV-infected MSM might not be reliable.

Many MSM, especially those infected with HIV, had multiple anal HPV types detected. HIV compromises the immunological responses of the body and results in even greater HPV positivity among HIV-infected MSM. Higher reinfection rates and lower clearance rates in HIV-positive MSM may also play a role [19]. The contribution of bacterial infections to HPV infection has not been well documented. Bacterial infections can cause inflammation in the mucosa of the anal canal and understandably facilitate the deposition of HPV in this area. Our study showed that anal bacterial infections, including chlamydia, gonorrhea, and mycoplasma, were associated with both higher anal HPV positivity and multiplicity of anal HPV types. Timely detection and treatment of bacterial infections may help reduce HPV transmission.

The positivities of high risk types including HPV 16, 18, and 52 and low risk types including HPV 6 and 11 were very high in the anal canal in participants, especially in those infected with HIV. The infections of these HPV types suggest high burdens of corresponding morbidities in the foreseeable future, including anal warts that may relapse, anal intraepithelial neoplasia, and even anal cancer. However, anal pap smears are not widely available yet in many clinical settings. A review found that only 2 out of 30 national HIV treatment guidelines included anal cancer screening for HIV-infected people [20]. A mathematical modelling demonstrated that screening for anal cancer by incorporating regular anal examinations into routine care for HIV-infected MSM is likely to be cost-effective by conventional standards. Regular anal exams for MSM, especially those living with HIV, to detect anal cancer earlier should be implemented [21].

It is noticeable that the great majority of HPV types detected were covered by both 4-valent and 9-valent HPV vaccines. High immunogenicity and tolerability of both 4-valent and 9-valent HPV vaccines was found in MSM aged 19–26 years. This implied that if vaccinated before sex debut, most of HPV cases in MSM in Guangzhou would be prevented by the two HPV vaccines. However, currently in China, the 2-valent HPV vaccine Cervarix manufactured by GlaxoSmithKline was recently approved by the China Food and Drug Administration (CFDA) and this will be the only HPV vaccine that
Table 4: Factors associated with detection of any HPV among men who have sex with men in Guangzhou.

| Risk factors                          | % (number of those with HPV/number of men) | Crude odds ratio (95% CI) | Adjusted odds ratio (95% CI) |
|---------------------------------------|-------------------------------------------|---------------------------|-----------------------------|
| Age at enrollment                     |                                            |                           |                             |
| 18–24                                 | 57.8 (37/64)                              | Ref                       |                             |
| 25–34                                 | 66.3 (57/86)                              | 1.43 (0.74–2.80)          | 1.45 (0.64–3.29)            |
| ≥35                                   | 78.6 (11/14)                              | 2.68 (0.68–10.53)         | 3.07 (0.63–14.99)           |
| Education level                       |                                            |                           |                             |
| Middle school or less                 | 78.1 (25/32)                              | Ref                       |                             |
| Technical diploma                    | 61.7 (29/47)                              | 0.45 (0.16–1.26)          |                             |
| University or above                   | 60.0 (51/85)                              | 0.42 (0.16–1.08)          |                             |
| Number of male sex partners in p3m*   |                                            |                           |                             |
| 0                                     | 63.6 (7/11)                               | Ref                       |                             |
| 1                                     | 61.0 (50/82)                              | 0.89 (0.24–3.30)          | 1.51 (0.33–7.04)            |
| ≥2                                    | 67.2 (41/61)                              | 1.17 (0.31–4.47)          | 1.17 (0.24–5.72)            |
| Frequency of condom use with          |                                            |                           |                             |
| male sex partners in p3m              |                                            |                           |                             |
| Always                                | 64.0 (55/86)                              | Ref                       |                             |
| Sometimes                             | 72.4 (42/58)                              | 1.48 (0.72–3.05)          | 1.15 (0.50–2.67)            |
| Never                                 | 40.0 (8/20)                               | 0.38 (0.14–1.02)          | 0.41 (0.12–1.40)            |
| Commercial sex experience             |                                            |                           |                             |
| Yes                                   | 45.5 (5/11)                               | 0.44 (0.13–1.52)          |                             |
| No                                    | 65.4 (100/153)                            | Ref                       |                             |
| STI detection*                        |                                            |                           |                             |
| Yes                                   | 74.4 (62/83)                              | 2.61 (1.35–5.05)**        | 2.51 (1.06–5.95)**          |
| No                                    | 53.1 (43/81)                              | Ref                       |                             |
| HIV status                            |                                            |                           |                             |
| Positive                              | 81.0 (64/79)                              | 4.58 (2.26–9.27)**        | 4.12 (1.82–9.32)**          |
| Negative                              | 48.2 (41/85)                              | Ref                       |                             |
| Frequency of drinking                 |                                            |                           |                             |
| Seldom or never                       | 65.3 (64/98)                              | Ref                       |                             |
| Sometimes                             | 60.0 (33/55)                              | 0.80 (0.40–1.57)          |                             |
| Every day or often                    | 72.7 (8/11)                               | 1.42 (0.35–5.69)          |                             |

Notes. **p < 0.05. STIs include anal chlamydia, anal gonorrhea, and anal mycoplasma. *0.05 < p < 0.10.

is available in the Chinese market. MSM in China are likely to take this vaccine and actively seek opportunities to get the 4-valent or 9-valent vaccine via other routes. Given that the age at first anal sex has been steadily decreasing [22], many MSM may miss the best age—an age before they commence their sexual life—to be vaccinated against HPV [23]. MSM media and MSM community organizations and clinicians should stand in the forefront of health education about HPV prevention in MSM.

The results in our study should be interpreted with caution. We used convenience sampling method to recruit participants and our sample may not represent general MSM in Guangzhou. The sample size was comparatively small which limited the statistical power in detecting additional factors associated with HPV positivity. As cross-sectional detection of HPV may be transient deposition only, it was hard to predict how many of the cases would persist. Our study attracted many MSM who experienced receptive anal sex. The majority of men (72%) in our study had receptive anal sex while only 44% had insertive anal sex, in the past 3 months. This may contribute to an overestimated anal HPV infection. Tabaco use had been demonstrated to be an independent risk factor for HPV infection in MSM [24]. We did not ask questions about cigarette smoking and were unable to account for this confounder. Studies showed that smoking rates in both HIV-infected and HIV-uninfected MSM were similar [25]. The missing of this variable was unlikely to cause biased risk for HPV infection when comparing the two groups of men.

Our study found high HPV positivity among MSM in Guangzhou, especially among those infected with HIV. The majority of these cases were potentially preventable by the
9-valent HPV vaccine. Regular anal exams and early HPV vaccination are warranted in MSM attending sexual health clinics in Guangzhou.

Competing Interests
All authors declare no competing interests.

Authors’ Contributions
This study was conceived and designed by Xuqi Ren, Wujian Ke, and Huachun Zou in consultation with the other authors. Xuqi Ren and Wujian Ke drafted the protocol. Ligang Yang and Bin Yang provided insights on clinic recruitment. Shujie Huang and Xiaolin Qin proofread the laboratory testing design. Xuqi Ren, Wujian Ke, and Huachun Zou drafted the manuscript with all authors critically reviewing the manuscript. This manuscript has not been previously published nor submitted elsewhere. Xuqi Ren and Wujian Ke contributed equally to this manuscript.

Funding
This work was supported by the Guangdong Provincial Health and Family Planning Commission (A2015028), Guangdong Provincial Center for Skin Disease & STI Control (2013–2016), and a grant from Australian National Health and Medical Research Commission Early Career Fellowship (APP1092621). The funding bodies had no role in study design, data collection and analysis, preparation of the manuscript, or the decision to publish.

Acknowledgments
The authors thank Lingnan Fellows Health Support Center for their kind assistance to the study and participants who kindly took part in the study. They also thank colleagues at Guangdong Provincial Center for Skin Disease & STI Control for their support during our study.

References
[1] H. Zou, C. K. Fairley, J. S. Hocking, S. M. Garland, A. E. Grulich, and M. Y. Chen, “The prevalence of anal human papillomavirus among young HIV negative men who have sex with men,” BMC Infectious Diseases, vol. 12, article 341, 2012.
[2] H. Zou, S. N. Tabrizi, A. E. Grulich et al., “Site-specific human papillomavirus infection in adolescent men who have sex with men (HYPER): an observational cohort study,” The Lancet Infectious Diseases, vol. 15, no. 1, pp. 65–73, 2015.
[3] A. G. Nyitray, R. J. Carvalho da Silva, M. L. Baggio et al., “Age-specific prevalence of and risk factors for anal human papillomavirus (HPV) among men who have sex with women and men who have sex with men: the HPV in men (HIM) study,” The Journal of Infectious Diseases, vol. 203, no. 1, pp. 49–57, 2011.
[4] D. A. Machalek, M. Poynten, F. Jin et al., “Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis,” The Lancet Oncology, vol. 13, no. 5, pp. 487–500, 2012.
[5] M. A. Stanley, D. M. Winder, J. C. Sterling, and P. K. C. Goon, “HPV infection, anal intra-epithelial neoplasia (AIN) and anal cancer: current issues,” BMC Cancer, vol. 12, article 398, 4 pages, 2012.
[6] L. S. Arroyo, M. Basaras, E. Arrese, S. Hernández, V. Esteban, and R. Cisterna, “Distribution of genital human papillomavirus genotypes in benign clinical manifestations among men from Northern Spain,” BMC Public Health, vol. 16, article 81, 8 pages, 2016.
[7] M. F. Schim van der Loeff, S. H. Mooij, O. Richel, H. J. C. de Vries, and J. M. Prins, “HPV and anal cancer in HIV-infected individuals: a review,” Current HIV/AIDS Reports, vol. 11, no. 3, pp. 250–262, 2014.
[8] Y. Hu, H.-Z. Qian, J. Sun et al., “Anal human papillomavirus infection among HIV-infected and uninfected men who have sex with men in Beijing, China,” Journal of Acquired Immune Deficiency Syndromes, vol. 64, no. 1, pp. 103–114, 2013.
[9] Y. Yang, X. Li, Z. Zhang et al., “Association of human papillomavirus infection and abnormal anal cytology among HIV-infected MSM in Beijing, China,” PLoS ONE, vol. 7, no. 4, Article ID e35983, 2012.
[10] X. Zhang, J. Yu, M. Li et al., “Prevalence and related risk behaviors of HIV, syphilis, and anal HPV infection among men who have sex with men from Beijing, China,” AIDS and Behavior, vol. 17, no. 3, pp. 1129–1136, 2013.
[11] X. Li, M. Li, Y. Yang et al., “Anal HPV/HIV co-infection among men who have sex with men: a cross-sectional survey from three cities in China,” Scientific Reports, vol. 6, Article ID 21368, 2016.
[12] Z. Li, H. Zhang, X. Li et al., “Anal human papillomavirus genotyping among HIV-positive men who have sex with men in Xian, China,” PLoS ONE, vol. 10, no. 4, Article ID e0125120, 2015.
[13] D.-Y. Zhang, Y.-P. Yin, T.-J. Feng et al., “HPV infections among MSM in Shenzhen, China,” PLoS ONE, vol. 9, no. 5, Article ID e96364, 2014.
[14] Guangzhou Economic and Social Development Statistics Bulletin 2015,(Chinese), http://www.gzstats.gov.cn/gzsq/201112/t20111229_431.html.
[15] C. Wang, L. Yang, A. Chen, Q. He, and L. Lin, “Qualitative investigation and multiplier methods on AIDS related information among the male homosexual in Guangzhou,” Journal of Diagnosis and Therapy on Dermato-venerology, vol. 21, pp. 333–336, 2014.
[16] X. Qin, H. Zheng, J. Huang et al., “Study on the infection and pathogenicity of Mycoplasma genitalium in sexually transmitted diseases clinic patients of Guangzhou,” International Journal of Epidemiology and Infectious Disease, vol. 42, no. 2, pp. 99–102, 2015.
[17] M. M. Manos, Y. Ding, D. K. Wright, J. Lewis, T. R. Broker, and S. M. Wolinsky, “The use of polymerase chain reaction amplification for the detection of genital human papillomaviruses,” Cancer Cells, vol. 7, pp. 209–214, 1989.
[18] M. Schiffman, G. Clifford, and F. M. Buonaguro, “Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline,” Infectious Agents and Cancer, vol. 4, article 8, 2009.
[19] A. A. R. Tobian, G. Kigozi, P. E. Gravitt et al., “Human papillomavirus incidence and clearance among HIV-positive and HIV-negative men in sub-Saharan Africa,” AIDS, vol. 26, no. 12, pp. 1555–1565, 2012.
[20] J. J. Ong, M. Chen, A. E. Grulich, and C. K. Fairley, “Regional and national guideline recommendations for digital ano-rectal
examination as a means for anal cancer screening in HIV positive men who have sex with men: a systematic review,” *BMC Cancer*, vol. 14, article 557, pp. 1–7, 2014.

[21] J. J. Ong, C. K. Fairley, S. Carroll et al., “Cost-effectiveness of screening for anal cancer using regular digital ano-rectal examinations in men who have sex with men living with HIV,” *Journal of the International AIDS Society*, vol. 19, no. 1, Article ID 20514, 2016.

[22] H. Zou, J. Xu, Q. Hu et al., “Decreasing age at first anal intercourse among men who have sex with men in China: a multicentre cross-sectional survey,” *Journal of the International AIDS Society*, vol. 19, no. 1, Article ID 20792, 2016.

[23] H. Zou, A. E. Grulich, A. M. Cornall et al., “How very young men who have sex with men view vaccination against human papillomavirus,” *Vaccine*, vol. 32, no. 31, pp. 3936–3941, 2014.

[24] H. Zou, S. N. Tabrizi, A. E. Grulich et al., “Early acquisition of anogenital human papillomavirus among teenage men who have sex with men,” *Journal of Infectious Diseases*, vol. 209, no. 5, pp. 642–651, 2014.

[25] W. Z. Akhtar-Khaleel, R. L. Cook, S. Shoptaw et al., “Trends and predictors of cigarette smoking among HIV seropositive and seronegative men: the multicenter aids cohort study,” *AIDS and Behavior*, vol. 20, no. 3, pp. 622–632, 2016.